PNV 0.78% $2.58 polynovo limited

The trial is being funded by medtech giant, Becton...

  1. 261 Posts.
    lightbulb Created with Sketch. 139
    The trial is being funded by medtech giant, Becton Dickinson.

    Becton Dickinson is a major competitor to J&J in the breast reconstruction space.

    The probability is now closer to 100% that SR teams up PNV with Ethicon (J&J) to do the same. I'd expect this news before Dec'2022. Yet another catalyst to ruin shorts. In the US markets, where small caps announce collaborations with majors, the sp goes vertical on the news... its even better when the major provides funding for trials biggrin.png
    Last edited by Albaicin: 04/08/22
 
watchlist Created with Sketch. Add PNV (ASX) to my watchlist
(20min delay)
Last
$2.58
Change
0.020(0.78%)
Mkt cap ! $1.780B
Open High Low Value Volume
$2.61 $2.63 $2.56 $2.465M 952.5K

Buyers (Bids)

No. Vol. Price($)
3 10700 $2.57
 

Sellers (Offers)

Price($) Vol. No.
$2.58 24502 5
View Market Depth
Last trade - 16.10pm 26/07/2024 (20 minute delay) ?
PNV (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.